Skip to content

Investigation the effect of trehalose on ALS

Investigation the effect of trehalose on function of an ALS patient

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20181022041407N6
Enrollment
1
Registered
2024-06-13
Start date
2024-07-22
Completion date
Unknown
Last updated
2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amiytrophic Lateral Sclerosis (ALS). Motor neuron disease

Interventions

Sponsors

Mashhad University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patient with ALS diagnosis (according to Gold Coast criteria) Obtaining the score of 0, 1, or 2 in each ALS-FRS item Satisfaction for participation in the research project

Exclusion criteria

Exclusion criteria: Uncontrolled and severe adverse event

Design outcomes

Primary

MeasureTime frame
Patient`s Function. Timepoint: baseline, after 3 months. Method of measurement: Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALS-FRS revised) questionnaire.

Secondary

MeasureTime frame
Assessment of lung function. Timepoint: Baseline and after 3 months. Method of measurement: Spirometry.;Interleukin-6. Timepoint: Baseline and after 3 months. Method of measurement: Blood test.;C-Reactive Protein (CRP). Timepoint: Baseline and after 3 months. Method of measurement: Blood test.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Emadzadeh

Mashhad University of Medical Sciences

maryamemadzadeh@yahoo.com+98 51 3841 7403

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026